Literature DB >> 19332521

Significance of tumour calcification in ovarian carcinoma.

G J C Burkill1, S D Allen, R P A'hern, M E Gore, D M King.   

Abstract

The purpose of this study was to assess the pattern and significance of tumour calcification in ovarian carcinoma. Patients with calcifying ovarian carcinoma were identified from radiological reports. Their tumour characteristics, serum calcium levels, treatment and survival were compared with a control group of patients with non-calcifying disease. Patterns and distribution of calcification were assessed. Available serial CT scans were reviewed for changes in both soft-tissue and calcified disease according to RECIST (response evaluation criteria in solid tumours) criteria where feasible. Temporal changes in calcification were correlated with changes in soft tissue disease and CA125 levels. The calcified group numbered 122 (22 other patients had calcifying tumour but insufficient clinical data). Calcification in ovarian carcinoma had a prevalence of 8% (144/1721) in our series. There was a significant difference (p<0.001) between the two groups in the distribution of histological type, with serous tumours being more common in the calcified group (74/122 (61%)) than in the controls (509/1498 (34%)). The calcified tumour patients tended to have lower grade disease (p<0.001). No differences between the groups were found for age, treatment or serum calcium levels. Distribution of calcification was diffusely peritoneal in 34 patients, in association with a pelvic mass in 15, nodal in 11 and within the anterior abdominal wall in 2. There was no correlation between changes in calcification on serial CT scans and corresponding CA125 levels. In conclusion, calcification tends to occur most commonly in serous cystadenocarcinomata and in tumours of lower grade. Changes in calcification cannot be used as a marker of disease response.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19332521     DOI: 10.1259/bjr/12716831

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  12 in total

1.  The role of FDG PET/CT in the evaluation of treatment response in a case of calcified ovarian metastases.

Authors:  Bahare Saidi; Babak Fallahi; Mohammad Eftekhari; Mahsa Ghorbani; Armaghan Fard-Esfahani
Journal:  Asia Ocean J Nucl Med Biol       Date:  2020

2.  Human ovarian carcinoma–associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production.

Authors:  Karen McLean; Yusong Gong; Yunjung Choi; Ning Deng; Kun Yang; Shoumei Bai; Lourdes Cabrera; Evan Keller; Laurie McCauley; Kathleen R Cho; Ronald J Buckanovich
Journal:  J Clin Invest       Date:  2011-08       Impact factor: 14.808

3.  Increase in post-therapy tumor calcification on CT scan is not an indicator of response to therapy in low-grade serous ovarian cancer.

Authors:  Dhakshinamoorthy Ganeshan; Priya Bhosale; Wei Wei; Preetha Ramalingam; Eniola Mudasiru-Dawodu; David Gershenson; Charlotte Sun; Revathy Iyer
Journal:  Abdom Radiol (NY)       Date:  2016-08

4.  Clinically Interpretable Radiomics-Based Prediction of Histopathologic Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma.

Authors:  Leonardo Rundo; Lucian Beer; Lorena Escudero Sanchez; Mireia Crispin-Ortuzar; Marika Reinius; Cathal McCague; Hilal Sahin; Vlad Bura; Roxana Pintican; Marta Zerunian; Stephan Ursprung; Iris Allajbeu; Helen Addley; Paula Martin-Gonzalez; Thomas Buddenkotte; Naveena Singh; Anju Sahdev; Ionut-Gabriel Funingana; Mercedes Jimenez-Linan; Florian Markowetz; James D Brenton; Evis Sala; Ramona Woitek
Journal:  Front Oncol       Date:  2022-06-16       Impact factor: 5.738

Review 5.  Multiple Pathways for Pathological Calcification in the Human Body.

Authors:  Netta Vidavsky; Jennie A M R Kunitake; Lara A Estroff
Journal:  Adv Healthc Mater       Date:  2020-12-04       Impact factor: 9.933

Review 6.  Malignant abdominal rocks: where do they come from?

Authors:  Joan M Cheng; Sree Harsha Tirumani; Kyung Won Kim; Sachin S Saboo; Juan C Baez; Atul B Shinagare
Journal:  Cancer Imaging       Date:  2013-12-11       Impact factor: 3.909

7.  Differentiation of epithelial ovarian cancer subtypes by use of imaging and clinical data: a detailed analysis.

Authors:  Yumiko Oishi Tanaka; Satoshi Okada; Toyomi Satoh; Koji Matsumoto; Akinori Oki; Tsukasa Saida; Hiroyuki Yoshikawa; Manabu Minami
Journal:  Cancer Imaging       Date:  2016-02-12       Impact factor: 3.909

8.  Novel population of small tumour-initiating stem cells in the ovaries of women with borderline ovarian cancer.

Authors:  Irma Virant-Klun; Martin Stimpfel
Journal:  Sci Rep       Date:  2016-10-05       Impact factor: 4.379

9.  Hypermetabolic Calcified Lymph Nodes on 18Fludeoxyglucose-Positron Emission Tomography/Computed Tomography in a Case of Treated Ovarian Cancer Recurrence: Residual Disease or Benign Formation?

Authors:  Alexandra Nikaki; Athanasios Alexopoulos; Fani Vlachou; Vasiliki Filippi; Ioannis Andreou; Vasiliki Rapti; Konstantinos Gogos; Konstantinos Dalianis; Roxani Efthymiadou; Vassilios Prassopoulos
Journal:  Mol Imaging Radionucl Ther       Date:  2016-06-05

10.  Switch of the ovarian cancer cell to a calcifying phenotype in the calcification of ovarian cancer.

Authors:  Jirui Wen; Zhiwei Zhao; Liwei Huang; Liang Li; Jiman Li; Ye Zeng; Jiang Wu; Yali Miao
Journal:  J Cancer       Date:  2018-02-28       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.